Impact of A1298C Polymorphism of Methylenetetrahydrofolate Reductase Gene on Risk of Congenital Heart Disorders in Iranian Population

  • Ebrahim Miri-Moghaddam Department of Molecular Medicine, Cardiovascular Diseases Research Center, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
  • Noor Mohammad Noori Department of Pediatric Cardiology, Children and Adolescent Health Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.
  • Yasaman Garme Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran .
  • Ali Bazi Clinical Research Development Unit, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran.
Keywords: Congenital heart disorders, Methylentetrahydrofolate reductase, Polymorphism, Tetralogy of Fallot, Ventricular septal defect

Abstract

Congenital heart disorders (CHDs) encompass inborn defects of the heart compartments. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene have continuously been reported as a modulating factor for CHDs. In a case-control study, the association of A1298C polymorphism of MTHFR gene with ventricular septal defect (VSD) and Tetralogy of Fallot (TOF), two common forms of CHDs, in the children of southeastern Iran was investigated. The presence of A1298C polymorphism was investigated using tetra-ARMS-PCR method, and statistical processes were carried out applying SPSS software (V:19). Males in the control group formed 40% and 60% (including 46.74% in VSD and 13.26% in in TOF). Although the association between gender and CHDs was not statistically significant, males had a higher risk of VSD (OR=1.7, 95% CI; 0.9-3.1, P=0.08). Overall frequency of AA, AC ,and CC genotypes of A1298C polymorphism were 55%, 43%, and 2% in CHDs patients respectively; while respective ratios were 50%, 48% and 2% in the controls (P>0.05). Patients with VSD were more commonly identified with AC+CC genotypes (52.8%) compared to TOF cases (23%, P=0.01). In stratified regression analysis, heterozygote genotype showed a significant protection against TOF (OR=0.3, 95% CI; 0.1-0.8, P=0.01). Frequency of variant allele was obtained 31.58% in CHD patients and 33.8% in the controls (P>0.05). Moreover, frequency of variant (C) allele was 35.2% in VSD compared to 18.8% in TOF (P>0.05). A1298C polymorphism of MTHFR gene seems to exert a significant protective effect against TOF.

References

Mahnaz Shahraki M, Bahareh Bagherzadeh M, Yalda Mirmesdagh M, Korosh Ghorbannejad M, Jahangiri A, Fard M. Clinical Course of Ventricular Septal Defect in Children Referred to Aliasghar Center of Zahedan during 2001-2011. The Iranian Journal of Cardiac Surgery.16.

Shahramian I, Noori NM, Hashemi M, Sharafi E, Baghbanian A. A study of serum levels of leptin, ghrelin and tumour necrosis factor-alpha in child patients with cyanotic and acyanotic, congenital heart disease. JPMA. 2013;63:1332-7.

Noori NM, Mahjoubifard M, Alavi SM, Teimouri A. Echocardiographic findings before and after surgical repair of Tetralogy of Fallot. JPMA The Journal of the Pakistan Medical Association. 2015;65(9):921-7.

Buskens E, Grobbee D, Frohn-Mulder I, Wladimiroff J, Hess J. Aspects of the aetiology of congenital heart disease. Eur Heart J. 1995;16(5):584-7.

Chen D, Qiao Y, Meng H, Pang S, Huang W, Zhang H, et al. Genetic analysis of the TBX3 gene promoter in ventricular septal defects. Gene. 2013;512(2):185-8.

Wang W, Hou Z, Wang C, Wei C, Li Y, Jiang L. Association between 5, 10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and congenital heart disease: A meta-analysis. Meta Gene. 2013;1:109-25.

Xuan C, Li H, Zhao J-X, Wang H-W, Wang Y, Ning C-P, et al. Association Between MTHFR Polymorphisms and Congenital Heart Disease: A Meta-analysis based on 9,329 cases and 15,076 controls. Sci Rep. 2014;4.

Szczeklik A, Sanak M, Jankowski M, Dropiński J, Czachór R, Musiał J, et al. Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet. 2001;101(1):36-9.

Hobbs CA, James SJ, Parsian A, Krakowiak PA, Jernigan S, Greenhaw JJ, et al. Congenital heart defects and genetic variants in the methylenetetrahydroflate reductase gene. J Med Genet. 2006;43(2):162-6.

Goldmuntz E, Woyciechowski S, Renstrom D, Lupo PJ, Mitchell LE. Variants of folate metabolism genes and the risk of conotruncal cardiac defects. Circ Cardiovasc Genet. 2008;1(2):126-32.

Shaw GM, Lu W, Zhu H, Yang W, Briggs FB, Carmichael SL, et al. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet. 2009;10(1):49.

Gu H, Gong J, Qiu W, Cao H, Xu J, Chen S, et al. Association of a tandem repeat polymorphism in NFATc1 with increased risk of perimembranous ventricular septal defect in a Chinese population. Biochem Genet. 2011;49(9-10):592-600.

van Driel LM, Verkleij‐Hagoort AC, de Jonge R, Uitterlinden AG, Steegers EA, van Duijn CM, et al. Two MTHFR polymorphisms, maternal B‐vitamin intake, and CHDs. Birth Defects Research Part A: Clinical and Molecular Teratology. 2008;82(6):474-81.

Wang B, Liu M, Yan W, Mao J, Jiang D, Li H, et al. Association of SNPs in genes involved in folate metabolism with the risk of congenital heart disease. J Matern Fetal Neonatal Med. 2013;26(18):1768-77.

Kotby A, Anwar M, El-Masry O, Awady M, El-Nashar A, Meguid N. Genetic variants in the methylenetetrahydrofolate reductase gene in Egyptian children with conotruncal heart defects and their mothers. Macedonian Journal of Medical Sciences. 2012;5(1):78-84.

van Beynum IM, Kapusta L, Bakker MK, den Heijer M, Blom HJ, de Walle HE. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J. 2010;31(4):464-71.

Sahiner UM, Alanay Y, Alehan D, Tuncbilek E, Alikasifoglu M. Methylene tetrahydrofolate reductase polymorphisms and homocysteine level in heart defects. Pediatr Int. 2014;56(2):167-72.

de Bree A, Verschuren WM, Bjorke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr. 2003;77(3):687-93.

Alazhary NM, Morsy MM, Al-Harbi KM. Angiotensin-converting enzyme gene insertion deletion (ACE I/D) polymorphism in Saudi children with congenital heart disease. Eur Rev Med Pharmacol Sci. 2015;19(11):2026-30.

Cresci M, Foffa I, Ait-Ali L, Pulignani S, Kemeny A, Gianicolo EA, et al. Maternal environmental exposure, infant GSTP1 polymorphism, and risk of isolated congenital heart disease. Pediatr Cardiol. 2013;34(2):281-5.

Zidan HE, Rezk NA, Mohammed D. MTHFR C677T and A1298C gene polymorphisms and their relation to homocysteine level in Egyptian children with congenital heart diseases. Gene. 2013;529(1):119-24.

Fang JY, Xiao SD. Folic acid, polymorphism of methyl-group metabolism genes, and DNA methylation in relation to GI carcinogenesis. J Gastroenterol. 2003;38(9):821-9.

van Beynum IM, den Heijer M, Blom HJ, Kapusta L. The MTHFR 677C->T polymorphism and the risk of congenital heart defects: a literature review and meta-analysis. QJM. 2007;100(12):743-53.

Zidan HE, Rezk NA, Mohammed D. MTHFR C677T and A1298C gene polymorphisms and their relation to homocysteine level in Egyptian children with congenital heart diseases. Gene. 2013;529(1):119-24.

Sayin Kocakap BD, Sanli C, Cabuk F, Koc M, Kutsal A. Association of MTHFR A1298C polymorphism with conotruncal heart disease. Cardiol Young. 2015;25(7):1326-31.

McBride KL, Fernbach S, Menesses A, Molinari L, Quay E, Pignatelli R, et al. A family‐based association study of congenital left‐sided heart malformations and 5, 10 methylenetetrahydrofolate reductase. Birth Defects Research Part A: Clinical and Molecular Teratology. 2004;70(10):825-30.

Christensen KE, Zada YF, Rohlicek CV, Andelfinger GU, Michaud JL, Bigras J-L, et al. Risk of congenital heart defects is influenced by genetic variation in folate metabolism. Cardiol Young. 2013;23(01):89-98.

Li X, Jin QL, Xu HQ, Zhang ZT, Zhou HJ, Yan DQ, et al. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. Experimental and Therapeutic Medicine. 2017;13(6):3624-30.

Published
2018-06-23
How to Cite
1.
Miri-Moghaddam E, Noori NM, Garme Y, Bazi A. Impact of A1298C Polymorphism of Methylenetetrahydrofolate Reductase Gene on Risk of Congenital Heart Disorders in Iranian Population. Acta Med Iran. 56(6):386-391.
Section
Articles